<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36690163</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2747</ISSN><JournalIssue CitedMedium="Internet"><Volume>194</Volume><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Brain research bulletin</Title><ISOAbbreviation>Brain Res Bull</ISOAbbreviation></Journal><ArticleTitle>Cell therapy in ALS: An update on preclinical and clinical studies.</ArticleTitle><Pagination><StartPage>64</StartPage><EndPage>81</EndPage><MedlinePgn>64-81</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.brainresbull.2023.01.008</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0361-9230(23)00012-6</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by the loss of motor neurons and neuromuscular impairment leading to complete paralysis, respiratory failure and premature death. The pathogenesis of the disease is multifactorial and noncell-autonomous involving the central and peripheral compartments of the neuromuscular axis and the skeletal muscle. Advanced clinical trials on specific ALS-related pathways have failed to significantly slow the disease. Therapy with stem cells from different sources has provided a promising strategy to protect the motor units exerting their effect through multiple mechanisms including neurotrophic support and excitotoxicity and neuroinflammation modulation, as evidenced from preclinical studies. Several phase I and II clinical trial of ALS patients have been developed showing positive effects in terms of safety and tolerability. However, the modest results on functional improvement in ALS patients suggest that only a coordinated effort between basic and clinical researchers could solve many problems, such as selecting the ideal stem cell source, identifying their mechanism of action and expected clinical outcomes. A promising approach may be stem cells selected or engineered to deliver optimal growth factor support at multiple sites along the neuromuscular pathway. This review covers recent advances in stem cell therapies in animal models of ALS, as well as detailing the human clinical trials that have been done and are currently undergoing development.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sironi</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, Milan 20156, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Marchi</LastName><ForeName>Fabiola</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology and ALS Centre, University of Piemonte Orientale, Maggiore Della Carit&#xe0; Hospital, Corso Mazzini 18, Novara 28100, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazzini</LastName><ForeName>Letizia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology and ALS Centre, University of Piemonte Orientale, Maggiore Della Carit&#xe0; Hospital, Corso Mazzini 18, Novara 28100, Italy. Electronic address: letizia.mazzini@uniupo.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bendotti</LastName><ForeName>Caterina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, Milan 20156, Italy. Electronic address: caterina.bendotti@marionegri.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Brain Res Bull</MedlineTA><NlmUniqueID>7605818</NlmUniqueID><ISSNLinking>0361-9230</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D033581" MajorTopicYN="N">Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bone marrow stem cells</Keyword><Keyword MajorTopicYN="N">Clinical trials</Keyword><Keyword MajorTopicYN="N">Hematopoietic stem cells</Keyword><Keyword MajorTopicYN="N">Mesenchymal stem cells</Keyword><Keyword MajorTopicYN="N">Neural stem cells</Keyword><Keyword MajorTopicYN="N">SOD1G93A transgenic rodents</Keyword><Keyword MajorTopicYN="N">Umbilical cord blood stem cells</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>23</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36690163</ArticleId><ArticleId IdType="doi">10.1016/j.brainresbull.2023.01.008</ArticleId><ArticleId IdType="pii">S0361-9230(23)00012-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>